These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21553105)

  • 21. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
    J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study.
    Li Z; Zhu H; Pang X; Mao Y; Yi X; Li C; Lei M; Cheng X; Liang L; Wu J; Ding Y; Yang J; Sun Y; Zhang T; You D; Liu Z
    BMC Cancer; 2022 Sep; 22(1):962. PubMed ID: 36076189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer.
    Liang Y; Wang W; Fang C; Raj SS; Hu WM; Li QW; Zhou ZW
    Oncotarget; 2016 Aug; 7(31):49565-49573. PubMed ID: 27385101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis.
    Lin PC; Lin JK; Lin CC; Wang HS; Yang SH; Jiang JK; Lan YT; Lin TC; Li AF; Chen WS; Chang SC
    Int J Colorectal Dis; 2012 Oct; 27(10):1333-8. PubMed ID: 22426691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.
    Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Watanabe T
    J Surg Res; 2016 Oct; 205(2):384-392. PubMed ID: 27664887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival.
    Nicolini A; Ferrari P; Duffy MJ; Antonelli A; Rossi G; Metelli MR; Fulceri F; Anselmi L; Conte M; Berti P; Miccoli P
    Arch Surg; 2010 Dec; 145(12):1177-83. PubMed ID: 21173292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer.
    Gao Y; Wang J; Zhou Y; Sheng S; Qian SY; Huo X
    Sci Rep; 2018 Feb; 8(1):2732. PubMed ID: 29426902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Value of Serum CEA, CA24-2 and CA19-9 in Patients with Colorectal Cancer.
    Rao H; Wu H; Huang Q; Yu Z; Zhong Z
    Clin Lab; 2021 Apr; 67(4):. PubMed ID: 33865243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer.
    Banfi G; Bravi S; Ardemagni A; Zerbi A
    Int J Biol Markers; 1996; 11(2):77-81. PubMed ID: 8776607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients?
    Stojkovic Lalosevic M; Stankovic S; Stojkovic M; Markovic V; Dimitrijevic I; Lalosevic J; Petrovic J; Brankovic M; Pavlovic Markovic A; Krivokapic Z
    Hell J Nucl Med; 2017; 20(1):41-45. PubMed ID: 28315907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
    Tocchi A; Costa G; Lepre L; Liotta G; Mazzoni G; Cianetti A; Vannini P
    J Cancer Res Clin Oncol; 1998; 124(8):450-5. PubMed ID: 9750022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
    Chen T; Zhang MG; Yu XJ; Liu L
    Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement.
    Yang XQ; Yan L; Chen C; Hou JX; Li Y
    Hepatogastroenterology; 2009; 56(94-95):1388-94. PubMed ID: 19950797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of related factors of prognosis after surgical treatment of patients with non-metastatic colorectal cancer and construction of a normagram prediction model].
    Liu SX; Zhang L; Shi YK; Han XH
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):167-172. PubMed ID: 35184461
    [No Abstract]   [Full Text] [Related]  

  • 37. Assessment of the value of preoperative serum levels of CA 242 and CEA in the staging and postoperative survival of colorectal adenocarcinoma patients.
    Kim SB; Fernandes LC; Saad SS; Matos D
    Int J Biol Markers; 2003; 18(3):182-7. PubMed ID: 14535588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.
    Gui JC; Yan WL; Liu XD
    Clin Exp Med; 2014 May; 14(2):225-33. PubMed ID: 23456571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CA19-9 is a significant prognostic marker of patients with stage III gastric cancer.
    Kambara Y; Miyake H; Nagai H; Yoshioka Y; Shibata K; Asai S; Yuasa N
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1918-1924. PubMed ID: 32814681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer.
    Song YF; Xu ZB; Zhu XJ; Tao X; Liu JL; Gao FL; Wu CL; Song B; Lin Q
    Clin Transl Oncol; 2017 Apr; 19(4):519-524. PubMed ID: 27743169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.